Hemophilia A Gene Therapy: BioMarin In Lead, Sangamo ‘Prays’ For Superior Results

Long-Term Efficacy Doubts Linger For Valrox

 
• By Andrew McConaghie

Gene therapy could transform hemophilia treatment, but competition is intense

Jefferies_Lobby
BioMarin and Sangamo were both presenting at the Jefferies conference in London

More from Gene Therapies

More from Advanced Therapies